Am J Cardiol. 2025 Sep 2:S0002-9149(25)00537-5. doi: 10.1016/j.amjcard.2025.08.064. Online ahead of print.
ABSTRACT
Despite the established clinical efficacy following intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI) than angiography-guided PCI, evidence regarding prognostic benefits of IVI-guided PCI in acute myocardial infarction (AMI) patients with high thrombus burden remains limited. Using the nationwide registries of KAMIR-NIH and KAMIR-V, we evaluated the prognostic impact of IVI-guided PCI in AMI patients with high thrombus burden. A total of 4,074 patients with AMI and TIMI thrombus grades 4 or 5 who underwent aspiration thrombectomy were selected, of whom 892 patients (21.9%) received IVI-guided PCI and 3,182 patients (78.1%) received angiography-guided PCI. Primary outcome was major adverse cardiovascular event (MACE, a composite of all-cause death, MI, repeat revascularization and stent thrombosis). Major secondary efficacy outcome was cardiac death and safety outcome was stroke at 3 years. During the median 3 years of follow-up, the risk of MACE was significantly lower in the IVI-guided PCI group than in the angiography-guided PCI group (12.9% vs. 16.3%; adjusted HR, 0.80; 95% CI, 0.65-0.98; P=0.035), mainly driven by a lower risk of all-cause death (5.7% vs. 10.0%; adjusted HR, 0.65; 95% CI, 0.48-0.89; P=0.007). IVI-guided PCI also showed lower risk of cardiac death compared with angiography-guided PCI (3.8% vs. 7.0%; adjusted HR, 0.65; 95% CI, 0.44-0.95; P=0.025). There was no significant difference in the risk of stroke between the groups. In this hypothesis generating study, IVI-guided PCI was associated with a lower risk of MACE and cardiac death than angiography-guided PCI in AMI patients with high thrombus burden.
PMID:40907857 | DOI:10.1016/j.amjcard.2025.08.064